Integrating PLCM strategy in Pharmaceutical Emerging Market

  • Sawagat Tripathy
  • Padala Narasimha Murthy
  • Bibhu Prasad Patra
DOI https://doi.org/10.22270/ijdra.v6i4.280

Abstract

All products and services must denote definite life cycles. The life cycle talks about the period from the product‘s first launch till it wind-up onto the market. Throughout this age noteworthy modifications are made in a way that the product is manifesting i.e. its mirror image with respect of sales. Ultimately increase of sustainable profit is the aim that every company aspires of the PLCM strategy. The understanding of a product‘s life cycle, can help a company to understand and realize when it is time to introduce and withdraw a product from a market, its position in the market compared to competitors, and the product‘s success or failure. This article details regarding Product Lifecycle Management in light of Pharmaceutical environment for the emerging markets (India, China, Russia, Brazil, and South Africa). Also an attempt has been made to compare PLCM of stated emerging countries with- highly regulated market (US).

Keywords: Product Lifecycle Management (PLCM), FDA, ANVISA, eCTD, CTD, ICH, Variation, CDER.

Downloads

Download data is not yet available.

References

1. Dureja H. New Drug Approval Process: Regulatory View [Internet]. pharmainfo.net; 2010 [cited 2017 Mar 17]. Available from: http://www.pharmainfo.net/reviews/new-drug-approval-process-regulatory-view 2. Prüfungsarbeit W. Regulatory strategies for life-cycle management of chemical defined cytostatic drugs with regard to the new pharmaceutical legislation – two case studies [Internet]. pharmainfo.net: Bonn; 2005 [cited 2017 May 15]. Available from: http://dgra.de/media/pdf/studium/masterthesis/master_rosenkranz_k.pdf 3. Drug discovery and development [Internet]. Nature. com; 2017 [cited 2016 Nov 17]. Available from: https://www.nature.com/subjects/drug-discovery-and-development 4. Morrisson & Forrestor LLP. Patent term extensions and regulatory exclusivities for pharmaceuticals in Asia and South America [Internet]. lexology.com; 2012 Jun 12 [cited 2017 May 15]. Available from:
http://www.lexology.com/library/detail.aspx?g=0a295b70-e577-461b-99e5-48e0eeeac512 5. Reddy TK & Reddy NK. Significance of Pharmaceutical Regulatory bodies - A Review [Internet]. 2017 [cited 2017 Nov 21]; 5(8):15-22. Available from:
http://www.pharmatutor.org/articles/significance-of-pharmaceutical-regulatory-bodies-a-review 6. Dureja H. New Drug Approval Process: Regulatory View [Internet]. pharmainfo.net; 2010 [cited 2017 Mar 17]. Available from:
http://www.pharmainfo.net/reviews/new-drug-approval-process-regulatory-view 7. Drug Development [Internet]. wikipedia.org; 2016 [cited 2016 Nov 18]. Available from:
https://en.wikipedia.org/wiki/Drug_development 8. Caroll O. Russia Regulatory Approval Process - Guide for Foreign Medicinal Products Manufacturers [Internet]. linkedin.com; 2016 Mar [cited 2017 May 25]. Available from:
https://www.linkedin.com/pulse/regulatory-approval-process-russia-expert-guide-olga-carroll-ph-d- 9. Vishal Gupta N et. al. Process of Approval of New Drug in India with emphasis on clinical trials. International Journal of Pharmaceutical Sciences Review and Research [Internet]. 2012 Apr [cited 2018 Mar 17]; 13(2):17-23. Available from:
Swagat et.al. International Journal of Drug Regulatory Affairs. 2018; 6(4):21-32
e-ISSN: 2321-6794 [32]
http://www.globalresearchonline.net/journalcontents/v13-2/004.pdf 10. Drug discovery and development [Internet]. nature.com; 2016 [cited 2016 Nov 17]. Available from:
https://www.nature.com/subjects/drug-discovery-and-development 11. CDER Handbook [Internet]. fda.gov; 1998 Jun [cited 2016 Nov 18]. Available from:
https://www.fda.gov/downloads/aboutfda/centersoffices/cder/ucm198415.pdf 12. Srivastava G. New Drug Approval Procedure in India [Internet]. linkedin.com; 2016 Nov [cited 2016 Dec 10]. Available from:
https://www.linkedin.com/pulse/new-drug-approval-procedure-india-garima-srivastava 13. Federal Food Drug Cosmetic Act, CFR 314.94(a)(12)(i)(A)(4) [Internet]. fda.gov [cited 2017 May 25]. Available from:
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplication 14. Eggleston K. Pharmaceutical Policy in China. Health Affairs [Internet]. Health Affairs; 2008 Aug [cited 2017 May 25]; 27(4):1042-1050. Available from: https://www.healthaffairs.org/doi/pdf/10.1377/hlthaff.27.4.1042. doi: doi.org/10.1377/hlthaff.27.4.1042 15. Discovery and Development. U.S Food and Drug Administration [Internet]. fda.gov; 2016 [cited 2016 Nov 17]. Available from:
https://www.fda.gov/forpatients/approvals/drugs/ucm405382.htm
Statistics
512 Views | 927 Downloads
How to Cite
Tripathy, S., P. N. Murthy, and B. P. Patra. “Integrating PLCM Strategy in Pharmaceutical Emerging Market”. International Journal of Drug Regulatory Affairs, Vol. 6, no. 4, Dec. 2018, pp. 21-32, doi:10.22270/ijdra.v6i4.280.
Issue
Vol 6 No 4 (2018): VOLUME 6, ISSUE 4, 2018
Section
Review
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.

I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.

Download link for COPYRIGHT FORM